Quality & complianceOfficial

Denagard Vet. 5000 ml oral solution faces Danish supply problems linked to higher demand

🇩🇰 DKMA · Fri 30 Oct 2026

DKMA says Elanco Denmark's tiamulin-based veterinary oral solution is in short supply, with disruption expected from late April to mid-November 2026 because of increased sales and demand.

The Danish Medicines Agency (DKMA) has reported current supply problems for Denagard Vet. 125 mg/ml oral solution in the 5000 ml pack size. The product is supplied by Elanco Denmark ApS.

According to the notice, the active substance is tiamulin, in the form of tiamulin hydrogen fumarate, and the ATC vet code is QJ01XQ01. The agency gives the cause of the disruption as increased sales and demand.

DKMA lists the expected period of supply difficulty as end of April to mid-November 2026. The notice was first published on 19 May 2026 and updated on 30 October 2026. The source does not say what the update changed.

The notice does not name alternative products, give details on stock levels or describe any measures to manage the shortage. DKMA directs questions about the current status to the company. The notice appears in the agency's section on supply of medicines, under veterinary notices for 2026.

What it means for your team

  • Regulatory and supply teams handling veterinary products in Denmark should note the expected disruption window, which runs to mid-November 2026, and check the current status with Elanco Denmark ApS.
  • The stated cause is increased demand rather than a quality or manufacturing issue, according to the notice.
  • The notice names no alternatives, so prescribers and distributors will need to seek product-specific guidance from the company.
  • The notice applies to the 5000 ml pack only; other presentations are not mentioned.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →